---
slug: 'novo-nordisk-dcf-valuation'
date: '01/01/2025'
title: 'Novo Nordisk DCF Valuation: Should you invest in the Ozempic and Wegovy Maker for exeptional returns?'
subtitle: "Novo Nordisk was breifly Europe's largest company by market cap. Then it declined 60% less than 6 months later. A century-old pharmacheutical enterprise constantly innovating in it's specialization in blood-related illness and diabetes, Novo Nordisk is investing heavily in scaling their existing businesses. At the same time, NVO is investing exceptionally heavily in finding cure for new illnesses. NVO's online prescription delivery business and international revenue segmant is showing impressive growth. Let's analyze Novo Nordisk fundamental and conduct an intrinsic valuation of the company."
categories: ['NVO', 'Novo Nordisk', 'Denmark', 'DCF Valuation', 'Signals', 'Intrinsic Valuation']
image: 'https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-3vb55nukya4g1.png?width=1587&format=png&auto=webp&s=32fe1bd929e5fbe311dcbf87674cce898cbc366e'
author: 'Kanchan'
---

# Introduction

In this article, we conduct an intrinsic cash-flow valuation of Novo Nordisk, a leading bio and pharmacheutical company in the world. Danish Kroner is the currency throughout this valuation. This is not an investment advice. Stock investments are risky. Please consult your financial advisor before making any investment decisions.

# A Primer on Novo Nordisk : The Company

Novo Nordisk is Denmark's largest company by market cap, second largest by revenue. The company's stock has multiple listing,in home country Denmark as [Novo Nordisk B](https://www.nasdaq.com/european-market-activity/shares/novo-b?id=TX2178) and the NYSE as [NVO](https://www.nyse.com/quote/XNYS:NVO). Novo Nordisk breifly became the largest euopean company by market cap in 2024. Ever since, the company's stock has been on a freefall, having declined more than 60% since All-time-highs.

## Novo Nordisk Revenue Breakdown by Product Category

Novo Nordisk generated 290 Billion DKK in 2024 full-year revenue with YoY growth rate at 25%. Their revenue can be broken down into threee segments as such:

- Diabetes Care accounting for 71% of total revneue, 19% growth rate in 2024.
- Obesity Care accounting for 22% of total revneue, 56% growth rate in 2024.
- Rare Diasease accounting for 6.4% of total revneue, 9% growth rate in 2024.

![Novo Nordisk Revenue Breakdown By Product Category](https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-q73hvt7umf4g1.png?width=653&format=png&auto=webp&s=159b387fd756875e384bcb4d9e31ff16dbab94b7)

> Novo Nordisk is the world's largest producer of insulin, having produced [50% of global insuin supply](https://www.novonordisk.com/about/what-we-do.html) in 2022. Insulin sales revenue grew 15% year of year in 2024 to 55.3 Billion DKK in 2024, representing a 19% revenue segment for the company.

## Novo Nordisk Growth Story - From Diabetes to Diabetes + Weight Loss

Insulin and Diabetes Care medications generated more than 75% of Novo Nordisk's total revenue in 2020. Add Wegovy to the mix and fast forward 2024, the segmant makes a whopping 92% of total revenue. Total revenue itself scaled up 2.5X in the past four years.

![Novo Nordisk 2020 and 2024 product mix by major products](https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-1vbkql6ntg4g1.png?width=596&format=png&auto=webp&s=51c45846a273fb732ed7b36dd4edd29ecccadff9)

Ozempic and Wegovy are Novo Nordisk's superhit drugs, accounting for more than 60% of total revenue in 2024. The following table provides an a further expanded breakdown by revenue, product, region, and growth rate.

### Novo Nordisk Revenue By Major Products 2020 and 2024

_Revenue in Millions of Danish Kroner (M DKK)_

| Segment / Product                     |   Year   | **Total Revenue (M DKK)** | **Int'l Revenue Portion (M DKK)** | **N. America Portion Revenue (M DKK)** | **% of Total Sales Combined** | **CAGR 2020-2024** |
| :------------------------------------ | :------: | :-----------------------: | :-------------------------------: | :------------------------------------: | :---------------------------: | :----------------: |
| **GLP-1 DIABETES**                    |          |                           |                                   |                                        |                               |                    |
| **Rybelsus®**                         | **2020** |           1,873           |                36                 |                 1,837                  |             1.5%              |     **84.3%**      |
|                                       | **2024** |          23,301           |              12,231               |                 11,070                 |             8.0%              |                    |
| **Ozempic®**                          | **2020** |          21,211           |               3,634               |                 17,577                 |             16.7%             |     **54.5%**      |
|                                       | **2024** |          120,342          |              29,055               |                 91,287                 |             41.4%             |                    |
| **Victoza®**                          | **2020** |          18,747           |               7,095               |                 11,652                 |             14.8%             |       -27.8%       |
|                                       | **2024** |           5,482           |               3,686               |                 1,796                  |             1.9%              |                    |
| **GLP-1 OBESITY**                     |          |                           |                                   |                                        |                               |                    |
| **Obesity Care** (Saxenda® & Wegovy®) | **2020** |           5,608           |               2,118               |                 3,490                  |             4.4%              |     **85.0%**      |
|                                       | **2024** |          65,146           |              16,988               |                 48,158                 |             22.4%             |                    |
| **TOTAL INSULIN**                     |          |                           |                                   |                                        |                               |                    |
| **Total Insulin**                     | **2020** |          56,550           |              38,352               |                 18,198                 |             44.5%             |       -0.5%        |
|                                       | **2024** |          55,373           |              38,978               |                 16,395                 |             19.1%             |                    |
| **RARE DISEASES**                     |          |                           |                                   |                                        |                               |                    |
| **Biopharm total** (Rare Diseases)    | **2020** |          18,926           |              11,648               |                 7,278                  |             14.9%             |       -0.4%        |
|                                       | **2024** |          18,639           |               9,437               |                 9,202                  |             6.4%              |                    |
| **TOTAL COMPANY REVENUE**             | **2020** |        **126,946**        |            **65,829**             |               **61,117**               |          **100.0%**           |     **22.8%**      |
|                                       | **2024** |        **290,403**        |            **112,231**            |              **178,172**               |          **100.0%**           |                    |

---

## Novo Nordisk Operating Margins, Return on Investment, Capex and Acquisitons

Revenue is not the only thing that scales uo with Novo Nordisk since 2020. A quick look the company's financal statements shows the following trajectory

- Operating profit scaled from 54 Billion DKK to 128 Bn DKK
- R&D expenses scaled from 17Bn DKK to 48Bn DKK
- Capital Expendites in forms of Property, Plant & Equipment (PP&E) scaled from 5.8Bn DKK in 2020 to 47Bn DKK in 2024.
- Novo Nordisk made three major acquisitons from 2020 - 2024
  - Dicerna Pharmaceuticals for 18Bn DKK in 2021
  - Forma Therapeutics for 70Bn DKK in 2022
  - Forma Therapeutics for a whopping 82Bn DKK in Q4 2024
